Literature DB >> 16719822

Topical imiquimod: mechanism of action and clinical applications.

David Vidal1.   

Abstract

Imiquimod is a synthetic imidazoquinoline heterocyclic amine of 240.3 Da (C14H16N4). Imiquimod is a cytokine inducer and a modifier of the innate immune response, as well as acquired antiviral and antitumor immune responses. Imiquimod 5% cream has proven to be an effective treatment for external genital warts, superficial basal cell carcinoma, and actinic keratosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719822     DOI: 10.2174/138955706776876131

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  9 in total

Review 1.  Toll-like receptors and B cells: functions and mechanisms.

Authors:  Claire M Buchta; Gail A Bishop
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 2.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 3.  Enhancing immune responses to tumor-associated antigens.

Authors:  Jack P Higgins; Michael B Bernstein; James W Hodge
Journal:  Cancer Biol Ther       Date:  2009-08-01       Impact factor: 4.742

4.  A Perspective on Imiquimod Microneedles for Treating Warts.

Authors:  Tsu-Man Chiu; Ping-Chun Hsu; Mohd Yaqub Khan; Cheng-An J Lin; Chun-Hung Lee; Tsai-Ching Hsu; Min-Hua Chen; Nobutaka Hanagata
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

5.  Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient.

Authors:  Shinsaku Imashuku; Miyako Kobayashi; Yoichi Nishii; Keisuke Nishimura
Journal:  Case Rep Dermatol Med       Date:  2018-01-03

6.  Treatment of Actinic Keratosis: The Best Choice through an Observational Study.

Authors:  Seung-Ah Yoo; Yeong-Ho Kim; Ju-Hee Han; Chul-Hwan Bang; Young-Min Park; Ji-Hyun Lee
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

7.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

8.  Presence of TRPA1 Modifies CD4+/CD8+ T Lymphocyte Ratio and Activation.

Authors:  Katalin Szabó; Ágnes Kemény; Noémi Balázs; Esam Khanfar; Zoltán Sándor; Ferenc Boldizsár; Rolland Gyulai; József Najbauer; Erika Pintér; Tímea Berki
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-01

Review 9.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.